Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia
DOI:
https://doi.org/10.15218/zjms.2020.042Keywords:
β-thalassemia, Deferasirox, Deferoxamine, Liver enzymes; FerritinAbstract
Background and objective: Patients on blood transfusion may develop complications related to iron overload and the effects of chelating agents (drugs), which adversely affect the liver in thalassemia, which is a genetic blood disorder of hemoglobin synthesis that causes severe anemia. This study aimed to assess the effect of deferasirox and deferoxamine drugs on liver enzyme activities (aspartate transaminase, alanine transaminase, and alkaline phosphatase), and serum ferritin level in β_thalassemic patients.
Methods: This study was carried out in Erbil city from October 2017 to February 2018. Blood specimens were collected in Hawler thalassemia center and Raparin hospital. The samples included 105 individuals; 70 β-thalassemic patients (35 treated by deferasirox as group A and 35 treated by deferoxamine as group B), and 35 healthy individuals (control group C).
Results: The serum aspartate transaminase and alkaline phosphatase activities in β-thalassemic patients were higher than that of controls. The serum alanine transaminase activity in the patients' groups showed non-significant elevation than that of controls. The serum ferritin level in the patients was significantly higher than that of controls.
Conclusion: Our finding showed that both deferasirox and deferoxamine drugs affect liver enzymes and increase ferritin level.
Metrics
References
Kanitta S, Saovaros S, Worrakavee C, Jim V, Phantip V, Suthat F, et al. Imbalanced globin chain synthesis determines erythroid cell pathology in thalassemic mice. Haematologica 2009; 94(9):1211–9.
Mathews C, Van Holde K, Kevin G. Biochemistry. 3rd ed. New York: An imprint of addition Wesley Longman Inc; 2000. P. 1930–31.
Cunningham M, Macklin E, Neufeld E, Cohen A. Complications of beta-thalassemia major in North America. Blood 2004; 104(1):34–9.
Pingsen Z, Heming W, Ruiqiang W. Molecular analysis of hemoglobinopathies in a large ethnic Hakka population in southern China. Medicine (Baltimore) 2018; 97(45):e13034.
Vanessa S, Manzon. Intensive course in Biological Anthropology 1st Summer School of the European Anthropological Association 2007; EAA Summer School eBook 1:115–25.
Maria D, Alan C, Antonio P, Mohamed B, Silverio P, Leyla A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with Beta-thalassemia. Blood 2006; 107:3455–62.
Tietz NW. Textbook of clinical chemistry. 3rd ed. Philadelphia: WB Saunders; 1999; P. 1699–703.
Debasish S, Rukmini M, Ravitosh R. Quantitative analysis of serum level alanine and aspartate aminotransferases, γ-glutamyl transferase and alkaline phosphatase as predictor of liver diseases. AIJRFANS 2015; 51–5.
Burtis CA, Bruns DE. Tietz fundamentals of clinical chemistry and molecular diagnostics. 4th ed. New York: Elsevier sounders; 2006. P. 1191.
Salama KM, Ibrahim OM, Kaddah AM, Boseila S, Ismail LA, Hamid MM. Liver enzymes in children with beta-thalassemia major: Correlation with iron overload and viral hepatitis. OA Maced J Med Sci 2015; 3(2):287–92.
Kowdley KV. Iron overload in patients with chronic liver disease. Gastroenterol Hepatol (N Y) 2016;12(11):695–8.
Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. World J Gastroenterol 2019; 25(5):521–38.
Mitchell R. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J 2016; 15:817–28.
Ashraf S, Mohamed Y, Fawzia Y, Lolwa N, Noora A, Aml S, et al. Longitudinal study on liver functions in patients with thalassemia major before and after deferasirox (DFX) therapy. Mediterr J. Hematol Infect Dis 2014; 6(1): e2014025.
Bayraker Y, Balkanci F, Ozenc A, Koseoglu T, Ozdemir A. The (pseudo-cholangiocarcinoma sign) in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels. Am J Gastrointestinal 1995; 90:2015–9.
Li C, Chik K, Lam C, To K, Yu S, Lee V, et al. Liver disease in transfusion dependent thalassaemia major. Arch Dis Child 2002; 86(5): 344–7.
Alkhateeb A, Conner J. Nuclear ferritin: A new role for ferritin in cell. Biology-Biochem. Biophys Acta 2010; 1800(8):793–7.
Huang X. Does iron has a role in breast cancer? Lancet Oncol 2008; 9(8):803–7.
Gangadhar T, Srikanth P, Suneetha Y. Predictive value of iron store markersin anemia of chronic kidney disease. Journal of Chemical and Pharmaceutical Research 2010; 2(3):400–10.
Nadeem S, Shah S, Touqueer I, Zafar I, Ejaz H. Serum transferrin receptor, serum ferritin and serum transferring receptor-ferritin index in adults with iron deficiency anaemia. J Ayub Med Coll Abbottabad 2011; 23(3):44–6.
Amanda J, Dorine W, Ina S, Jack F. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol Dial Transplant 2004; 19(11):2754–60.
Markovic M, Majkic-Singh N, Lgnjatovic S, Singh S. Reticulocyte hemoglobin content versus soluble transferrin receptor and ferritin index in iron deficiency anemia accompanied with inflammation. Int J Lab Hematol 2007; 29:341–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Rasul Jameel Ali, Dler Rostum Ali, Zhyan Ismail Ahmed, Amal Aziz Ahmed, Dilvin Saleh Hassen, Rozy Mohammed Tahir (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
